Prof Chris McGuigan - BSc PhD
ABPI Annual Lecture for 2012
Ups and Downs of a Drug Hunter - from the Lab to Patients
News Flash
New first in man, trial for anti-cancer ProTide, with Nucana Biomed, started November 2012.
Related Links
Chris McGuigan's Lab page
The Presidents Research Scholarships
The Research Excellence Framework (REF)
Qualifications
Professor Chris McGuigan graduated Bachelor of Science in 1979 with First Class Honours from the University of Birmingham where he also obtained his Ph.D. in Anticancer Drug Design, 1982.
Research Interests
• Major interest in new drug discovery and development for HIV, hepatitis B and C, herpes, cancer and osteoarthritis. This involves synthetic organic and organo-phosphorus chemistry, purification methods and spectroscopy, particularly high field NMR, and close collaboration with virologists and biochemists throughout Europe, and USA.
• Antiviral Drug Discovery via ProTides. Our collaborative project with GSK, NC has now completed. Major potency enhancements were observed with a number of GSK's agents.
FV100. The World's most potent inhibitor of VZV (cause of chickenpox and shingles). Our lab discovered this agent and out-licensed it to New York based Fermavir now Inhibitex. See - FV100 - the story
INX189. The most powerful inhibitor of hepatitis C virus in its class. Discovered in our lab in 2008 and now outlicensed to Inhibitex and entered phase 2 trials with BMS.
Member of the School's Medicinal Chemistry Research Discipline
Teaching Profile
I lecture to all 4 years of the M.Pharm. Degree:
• M.Pharm 1. Module 1123 - Nucleic Acids: Structure and function
• M.Pharm 2. Module 2106 - Pro-Drugs. Module 2108 - NMR
• M.Pharm 3. Module 3101 - Chirality and Drug Action, Antivirals
• M.Pharm 4. Module 4112 - Workshops on Med.Chem. Module 4112 - Publication workshop,
NMR workshop.
We also run 3 M.Pharm. Research Projects in our laboratory each year,